Room Temperature Logistics Claims: Verification for Indian Conditions
Evaluating manufacturer claims about room-temperature transport stability for molecular diagnostic reagents in Indian l…
Tuberculosis Drug Resistance — Molecular Diagnostics
The iFIND platform enables rapid detection of M. tuberculosis complex and rifampicin resistance (TBR kit), with expanded resistance detection for isoniazid and fluoroquinolones (IFQ kit).
Document discrepancy identified.
One or more sources provide contradictory information. See the evidence boundary section below for details.
Conflicts are documented and published transparently, not hidden.
Local problem
India has one of the highest TB burdens globally, with increasing rates of drug-resistant TB.
Chinese solution scope
The iFIND molecular diagnostics platform: TBR kit for M. tuberculosis complex and rifampicin resistance detection; IFQ kit for isoniazid and fluoroquinolone resistance detection.
Evidence boundary
All technical parameters are manufacturer-provided. Independent evaluation for the Indian market is in planning stage. IS1081/IS1087 target conflict and detection time discrepancy (85 min vs ≤120 min) are unresolved.
Local implementation gap
CDSCO registration not checked. Local service and Hindi documentation not available.
Sources and evidence
All technical parameters are manufacturer-provided unless otherwise stated.
- Manufacturer document Manufacturer-provided information Technical specifications, brochures, and IFU documents provided by the manufacturer (Kunpeng Gene / iFIND).
- Document discrepancy Document discrepancy identified Conflicting information exists between manufacturer sources. See evidence boundary above.